Literature DB >> 25758021

The STING pathway and the T cell-inflamed tumor microenvironment.

Seng-Ryong Woo1, Leticia Corrales1, Thomas F Gajewski2.   

Abstract

A major subset of patients with advanced solid tumors show a spontaneous T cell-inflamed tumor microenvironment, which has prognostic import and is associated with clinical response to immunotherapies. As such, understanding the mechanisms governing the generation of spontaneous T cell responses in only a subset of patients is critical for advancing immunotherapeutic approaches further. Here, we discuss the characteristics of T cell-inflamed versus non-inflamed tumors, including a type I interferon (IFN) signature associated with T cell priming against tumor antigens. We review recent findings that have pointed towards the STING (stimulator of interferon genes) pathway of cytosolic DNA sensing as an important innate immune sensing mechanism driving type I IFN production in the tumor context. Knowledge of this pathway is guiding the further development of novel immunotherapeutic strategies.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25758021      PMCID: PMC4393801          DOI: 10.1016/j.it.2015.02.003

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  72 in total

1.  Effector memory T cells, early metastasis, and survival in colorectal cancer.

Authors:  Franck Pagès; Anne Berger; Matthieu Camus; Fatima Sanchez-Cabo; Anne Costes; Robert Molidor; Bernhard Mlecnik; Amos Kirilovsky; Malin Nilsson; Diane Damotte; Tchao Meatchi; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Jérôme Galon
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

2.  Intrinsic self-DNA triggers inflammatory disease dependent on STING.

Authors:  Jeonghyun Ahn; Phillip Ruiz; Glen N Barber
Journal:  J Immunol       Date:  2014-09-26       Impact factor: 5.422

3.  A critical function for type I interferons in cancer immunoediting.

Authors:  Gavin P Dunn; Allen T Bruce; Kathleen C F Sheehan; Vijay Shankaran; Ravindra Uppaluri; Jack D Bui; Mark S Diamond; Catherine M Koebel; Cora Arthur; J Michael White; Robert D Schreiber
Journal:  Nat Immunol       Date:  2005-06-12       Impact factor: 25.606

4.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

5.  Prevention of allogeneic fetal rejection by tryptophan catabolism.

Authors:  D H Munn; M Zhou; J T Attwood; I Bondarev; S J Conway; B Marshall; C Brown; A L Mellor
Journal:  Science       Date:  1998-08-21       Impact factor: 47.728

6.  Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid.

Authors:  Joseph Conlon; Dara L Burdette; Shruti Sharma; Numana Bhat; Mikayla Thompson; Zhaozhao Jiang; Vijay A K Rathinam; Brian Monks; Tengchuan Jin; T Sam Xiao; Stefanie N Vogel; Russell E Vance; Katherine A Fitzgerald
Journal:  J Immunol       Date:  2013-04-12       Impact factor: 5.422

7.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

Authors:  P van der Bruggen; C Traversari; P Chomez; C Lurquin; E De Plaen; B Van den Eynde; A Knuth; T Boon
Journal:  Science       Date:  1991-12-13       Impact factor: 47.728

8.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

9.  STING manifests self DNA-dependent inflammatory disease.

Authors:  Jeonghyun Ahn; Delia Gutman; Shinobu Saijo; Glen N Barber
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-06       Impact factor: 11.205

10.  PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Authors:  Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

View more
  83 in total

1.  Comprehensive analysis of a chemokine- and chemokine receptor family-based signature for patients with lung adenocarcinoma.

Authors:  Tao Fan; Yu Liu; Hengchang Liu; Liyu Wang; He Tian; Yujia Zheng; Bo Zheng; Liyan Xue; Fengwei Tan; Qi Xue; Shungeng Gao; Chunxiang Li; Jie He
Journal:  Cancer Immunol Immunother       Date:  2021-05-11       Impact factor: 6.968

Review 2.  The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications.

Authors:  Panagiota Economopoulou; Christos Perisanidis; Evaggelos I Giotakis; Amanda Psyrri
Journal:  Ann Transl Med       Date:  2016-05

Review 3.  Lymphotoxin signalling in tertiary lymphoid structures and immunotherapy.

Authors:  Haidong Tang; Mingzhao Zhu; Jian Qiao; Yang-Xin Fu
Journal:  Cell Mol Immunol       Date:  2017-04-17       Impact factor: 11.530

Review 4.  Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers.

Authors:  Claire Vanpouille-Box; Silvia C Formenti; Sandra Demaria
Journal:  Clin Cancer Res       Date:  2017-07-27       Impact factor: 12.531

Review 5.  Chemo-Immunotherapy: Role of Indoleamine 2,3-Dioxygenase in Defining Immunogenic Versus Tolerogenic Cell Death in the Tumor Microenvironment.

Authors:  Theodore S Johnson; Tracy Mcgaha; David H Munn
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

Review 6.  Telltale tumor infiltrating lymphocytes (TIL) in oral, head & neck cancer.

Authors:  Yu Lei; Yuying Xie; Yee Sun Tan; Mark E Prince; Jeffrey S Moyer; Jacques Nör; Gregory T Wolf
Journal:  Oral Oncol       Date:  2016-08-21       Impact factor: 5.337

7.  STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy.

Authors:  Lekh N Dahal; Lang Dou; Khiyam Hussain; Rena Liu; Alexander Earley; Kerry L Cox; Salome Murinello; Ian Tracy; Francesco Forconi; Andrew J Steele; Patrick J Duriez; Diego Gomez-Nicola; Jessica L Teeling; Martin J Glennie; Mark S Cragg; Stephen A Beers
Journal:  Cancer Res       Date:  2017-05-16       Impact factor: 12.701

8.  Improving STING Agonist Delivery for Cancer Immunotherapy Using Biodegradable Mesoporous Silica Nanoparticles.

Authors:  Kyung Soo Park; Cheng Xu; Xiaoqi Sun; Cameron Louttit; James J Moon
Journal:  Adv Ther (Weinh)       Date:  2020-07-21

9.  STING signalling protects against chronic pancreatitis by modulating Th17 response.

Authors:  Qinglan Zhao; Murli Manohar; Yi Wei; Stephen J Pandol; Aida Habtezion
Journal:  Gut       Date:  2019-01-31       Impact factor: 23.059

10.  Deregulation of STING Signaling in Colorectal Carcinoma Constrains DNA Damage Responses and Correlates With Tumorigenesis.

Authors:  Tianli Xia; Hiroyasu Konno; Jeonghyun Ahn; Glen N Barber
Journal:  Cell Rep       Date:  2015-12-31       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.